All Forms of Hormone Replacement Therapy (HRT) Increase Breast Cancer Risk
July 11, 2010 by admin
Filed under Breast Cancer, HRT, Hormone Replacement Therapy, Weekly Health Update
Welcome to Weekly Health Update“A critical weekly review of important new research findings for health-conscious readers” ALL FORMS OF HORMONE REPLACEMENT THERAPY (HRT) INCREASE BREAST CANCER RISK One of the most common questions that I am asked is if there are any safe forms of hormone replacement therapy (HRT) for women who are experiencing severe symptoms associated with menopause. Since the release of the preliminary results of the pivotal Women’s Health Initiative study, in 2002, which clearly showed that standard combination HRT (containing the two primary female sex hormones) was associated with a significant increase in the risk of developing breast cancer, a number of alternative “safer” forms of HRT have been proposed. These alternative forms of HRT have included transdermal estrogen patches (which are placed on the skin) and other forms of “bioidentical” HRT hormones. Advocates of transdermal estrogen patches note that the adverse effects of estrogen-based HRT pills on cholesterol, as well as their association with an increased risk of life-threatening blood clots, may be lower with transdermal patches when compared to oral HRT medications. Proponents of “bioidentical” HRT, in which the active ingredient is the same chemical form of estrogen (estradiol) that is manufactured in the ovaries prior to menopause, have also made abundant health-related claims for this form of HRT when compared to the more commonly prescribed cocktail of mixed forms of estrogen derived from the urine of pregnant mares. Unfortunately, there is almost no solid clinical research evidence available to support these claims that “bioidentical” HRT is safer, or more effective, than the more commonly prescribed “conjugated equine estrogens.” (Within the estrogen-sensitive cells of a woman’s body, estrogen receptors really don’t care much whether estrogen-like hormones come from horse urine or from the human form of estrogen; nor do they care whether or not estrogen-like hormones enter the body in the form of a pill versus being absorbed into the bloodstream through a transdermal patch.) As the Women’s Health Initiative study’s breast cancer risk findings were far more robust for the combination HRT pill that has been commonly prescribed for menopausal women (because estrogen-alone HRT increases the risk of uterine cancer, as well…), many patients, and their doctors, have held out the hope that low-dose estrogen-only HRT might be a safer alternative to traditional combination HRT. However, a recently published research paper from the enormous European EPIC public health study casts serious doubt about the assumption that alternative forms of HRT are safe from the standpoint of breast cancer risk. This research paper, which has been published in the International Journal of Cancer, is an update of the huge European Prospective Investigation into Cancer and Nutrition (EPIC) study, in which 134,744 postmenopausal women throughout Europe were evaluated. After nearly 9 years of follow-up, on average, 4,312 new cases of breast cancer were diagnosed within this extremely large group of patient volunteers. When compared to women who had never used HRT, the women who were currently using combination HRT during the course of this clinical study experienced a 77 percent increase in the relative risk of developing breast cancer (similar to what has been shown in the Women’s Health Initiative study, and in other similar prospective clinical research studies). However, the greater contribution of this study to our understanding of the risks of HRT was the finding that estrogen-only HRT also increased the risk of breast cancer, as there was a 42 percent increase in the relative risk of breast cancer among the women who were taking various forms of estrogen-only HRT. Moreover, this increased breast cancer risk among users of estrogen-only HRT was the same for both oral and transdermal forms of estrogen-only HRT. The results of this giant, multi-national prospective public health study are of great importance, as it is many times larger than most of the studies that have preceded it, including the Women’s Health Initiative study. These results from the ongoing EPIC study emphasize the point that I have made to patients for almost two decades, now: The biology of the receptors in cells that respond to estrogen, and other estrogen-like molecules, has been well understood for decades now. Any substance that stimulates these estrogen receptors automatically sets off a cascade of biochemical reactions with the same end biological result. We have long known that prolonged exposure to estrogen (whether from a woman’s own ovaries, or from HRT medications) increases the risk of breast and uterine cancer, and also increases the risk of blood clots, gallstones, and other serious illnesses. (More recent data has also implicated combination HRT in the development of cardiovascular disease and dementia in women.) Based upon the findings of this very large prospective public health study, my advice to women remains the same as it has been for almost 20 years. If you are going through menopause, do not use HRT medications. If you are already using HRT medications, then ask your doctor to help in weaning you off of them. If you are one of the approximately 3 to 5 percent of postmenopausal women who have unbearably severe hot flashes, or other severe symptoms of menopause, and you are currently using some form of HRT medication, then work with your doctor to reduce the dose of your HRT medicine to the lowest possible level that adequately treats your symptoms.
For more information on HRT and cancer, please click on the following links to my previous columns on this topic: Hormone Replacement Therapy (HRT) & Ovarian Cancer Hormone Replacement Therapy (HRT) & Breast Cancer; Stool DNA Testing & Cancer of the Colon & Rectum Minority Women, Hormone Replacement Therapy & Breast Cancer; Does Health Insurance Improve Health?
To learn more about the critical role of hormone replacement medications and the risk of cancer, look for the publication of my new landmark book, “A Cancer Prevention Guide for the Human Race,” in the summer of this year. Disclaimer: As always, my advice to readers is to seek the advice of your physician before making any significant changes in medications, diet, or level of physical activity Dr. Wascher is an oncologic surgeon, a professor of surgery, a cancer researcher, an oncology consultant, and a widely published author For a different perspective on Dr. Wascher, please click on the following YouTube link: http://www.youtube.com/watch?v=7-Tdv7XW0qg I and the staff of Weekly Health Update would like to take this opportunity to thank the more than 100,000 new and returning readers who visit our premier global health information website every month. As always, we enjoy receiving your stimulating feedback and questions, and I will continue to try and personally answer as many of your inquiries as I possibly can. |
|
|
Soy, Curcumin & Prostate Cancer Risk
June 27, 2010 by admin
Filed under Isoflavones, Soy, Weekly Health Update, curcumin, prostate cancer
Welcome to Weekly Health Update“A critical weekly review of important new research findings for health-conscious readers” SOY, CURCUMIN & PROSTATE CANCER RISK Because chronic inflammation within the prostate gland is through to be an important risk factor for prostate cancer, anti-inflammatory dietary supplements and medications may be able to reduce the risk of prostate cancer by reducing inflammation. Isoflavones from soy-based foods are known to act as a weak form of estrogen (the dominant female sex hormone). Based upon this estrogen-like behavior, as well as potential anti-inflammatory properties, soy isoflavones are being studied as possible prevention and treatment agents for prostate cancer, and other types of cancer. Curcumin, which is present in the Indian curry spice turmeric, is also known to have potent anti-inflammatory properties, and has also been the subject of considerable cancer prevention and cancer treatment research. A newly published prospective, randomized, blinded, placebo-controlled research study, published in the current issue of the journal Prostate, suggests that the combination of soy isoflavones and curcumin may have important potential prostate cancer prevention properties. In the first part of this study, human prostate cancer cells were treated with a combination of soy isoflavones and curcumin. Treatment of these human cancer cells with soy isoflavones and curcumin resulted in a significant reduction of prostate-specific antigen (PSA) production by these malignant cells (PSA is a marker of both prostate gland inflammation and prostate gland cancer). As regular readers of this column are already aware, treatments performed in the laboratory that have beneficial effects on cancer cells, or on mice or rats, do not always have the same positive effects on living, breathing human beings. Therefore, the findings of the second part of this study are of particular interest. A total of 85 men with elevated PSA levels, but without prostate cancer (as confirmed by prostate biopsy), were enrolled in the second phase of this intriguing small study. These 85 men were divided into two groups, and one group received daily supplements containing both soy isoflavones and curcumin, while the second (control) group of men received placebo (sugar) pills that were identical in appearance to the supplement pills (neither the 85 men, nor the nurses who dispensed the supplement pills and placebo pills, were aware of which pills each study volunteer was receiving until after the research study had been completed). PSA blood levels were tested at the beginning of the clinical portion of this study, and once again 6 months later. As was observed in the prostate cancer cells during the first part of this study, men with a PSA level of 10, or higher, experienced a significant reduction in their blood PSA levels 6 months after starting daily supplementation with soy isoflavones and curcumin. Although this brief study cannot definitively confirm that soy isoflavone and curcumin supplements reduce the risk of prostate cancer, their ability to reduce elevated PSA levels in men with chronic prostate inflammation, but without evidence of prostate cancer, at least suggests a potential role in the prevention of prostate cancer (presumably through a reduction in prostate gland inflammation). While there are multiple human research studies underway that are evaluating the effectiveness of soy isoflavones as cancer prevention agents, currently, there are no major human studies looking at the effects of curcumin on prostate cancer risk. Based upon the findings of this small, interesting study of soy isoflavones and curcumin, which suggest a potential additive effect on PSA reduction when both of these dietary supplements are taken together, human research trials should be developed to look at the long-term impact, if any, of combined soy isoflavone and curcumin supplementation on prostate cancer risk.
For additional research information on soy isoflavones and curcumin in cancer prevention and cancer treatment, please review the following previous columns: Soy Foods & Stomach Cancer Risk Cruciferous Vegetables, Soy & Breast Cancer Risk Soy Isoflavones & Recurrent Prostate Cancer Soy Isoflavones Decrease Breast Cancer Recurrence Risk Genistein (Soy Isoflavone) & Prostate Cancer Diet, Soy & Breast Cancer Risk To learn more about the role of soy isoflavones and curcumin in the prevention of cancer, look for the publication of my new landmark book, “A Cancer Prevention Guide for the Human Race,” in the summer of this year.
Disclaimer: As always, my advice to readers is to seek the advice of your physician before making any significant changes in medications, diet, or level of physical activity Dr. Wascher is an oncologic surgeon, a professor of surgery, a cancer researcher, an oncology consultant, and a widely published author For a different perspective on Dr. Wascher, please click on the following YouTube link: http://www.youtube.com/watch?v=7-Tdv7XW0qg I and the staff of Weekly Health Update would like to take this opportunity to thank the more than 100,000 new and returning readers who visit our premier global health information website every month. As always, we enjoy receiving your stimulating feedback and questions, and I will continue to try and personally answer as many of your inquiries as I possibly can. |
|
|
Soy Foods & Stomach Cancer Risk
May 9, 2010 by admin
Filed under Weekly Health Update
Welcome to Weekly Health Update“A critical weekly review of important new research findings for health-conscious readers”
SOY FOODS & STOMACH CANCER RISK There is a great deal of interest regarding the potential effects of soy-based foods (like tofu and soy beverages) on cancer risk. As discussed in my forthcoming book (“A Cancer Prevention Guide for the Human Race”), there is a growing body of laboratory and human research data suggesting that dietary soy isoflavones might be able to reduce the risk of prostate and breast cancer. Now, a newly published clinical research study from Korea suggests that high levels of soy isoflavones in the blood may also be linked to a reduced risk of stomach cancer, as well. (Korea has one of the highest incidences of stomach cancer in the world.) This study appears in the current issue of the journal Cancer Epidemiology, Biomarkers & Prevention. As most of the published research in the area of cancer prevention is based upon the subjective recall of patient volunteers regarding their diet (and other habits), the authors of this study chose, instead, to directly measure the levels of soy isoflavones in the blood of patient volunteers. This study included 131 patients with recently diagnosed stomach cancer, and 393 “control” patients who did not have stomach (gastric) cancer. Blood levels of the two major dietary soy isoflavones (genistein and daidzein) were directly measured in all 524 of these research volunteers, and these results were compared between the patients with stomach cancer and the “control” patients without gastric cancer. Study volunteers with the highest levels of genistein in their blood, when compared with those with the lowest levels, were found to be 46 percent less likely to be diagnosed with stomach cancer. Even more impressive was the finding that study volunteers with the highest daidzein blood levels were 79 percent less likely to be diagnosed with stomach cancer when compared to the volunteers with the lowest levels of daidzen in their blood While there may be other health-related factors at work among the study volunteers with high levels of soy isoflavones in their blood that could explain the much lower stomach cancer risk observed in these same patients, this study’s results are nonetheless intriguing enough to justify a large scale, prospective, randomized, placebo-controlled soy isoflavone clinical research study to confirm the findings of this relatively small Korean public health study.
To learn more about the role of soy isoflavones as potential cancer prevention nutrients, look for the publication of my new landmark evidence-based book, “A Cancer Prevention Guide for the Human Race,” in the summer of this year.
Disclaimer: As always, my advice to readers is to seek the advice of your physician before making any significant changes in medications, diet, or level of physical activity Dr. Wascher is an oncologic surgeon, a professor of surgery, a cancer researcher, an oncology consultant, and a widely published author For a different perspective on Dr. Wascher, please click on the following YouTube link: http://www.youtube.com/watch?v=7-Tdv7XW0qg I and the staff of Weekly Health Update would like to take this opportunity to thank the nearly 120,000 new and returning readers who visited our premier global health information website last month. As always, we enjoy receiving your stimulating feedback and questions, and I will continue to try and personally answer as many of your inquiries as I possibly can. |
|
|
Cruciferous Vegetables, Soy & Breast Cancer Risk
April 11, 2010 by admin
Filed under Weekly Health Update
Welcome to Weekly Health Update“A critical weekly review of important new research findings for health-conscious readers”
CRUCIFEROUS VEGETABLES, SOY & BREAST CANCER RISK
The role of soybean-derived isoflavones in cancer prevention is not entirely clear at this time. However, there has been intense interest in tofu, and other soy-derived foods, as potential breast cancer prevention agents. At the same time, because genistein, and other soy isoflavones, are known to variably act as both inhibitors and mimics of estrogen (the primary female sex hormone), cancer experts remain divided regarding the safety of regularly consuming soy isoflavones by women who are at an increased risk of developing breast cancer (chronic estrogen stimulation of the breast is a known risk factor for breast cancer). Meanwhile, the high level of tofu consumption among women in the Far East, coupled with the much lower incidence of breast cancer in those countries when compared to the United States and other western countries, has fuelled speculation that tofu and other soy-derived foods may actually be associated with a reduced risk of breast cancer. In addition to soy isoflavones, there is also research data available suggesting that the frequent consumption of cruciferous vegetables, like broccoli and cauliflower, may also be associated with a decreased risk of at least some types of cancer, including breast cancer. A newly published public health study from Singapore evaluated the impact of the regular intake of vegetables, fruit, and soy-derived foods on the risk of breast cancer within the large Chinese population in that country. This enormous prospective epidemiological study, which began in 1993, and which appears in the current issue of the American Journal of Clinical Nutrition, included more than 34,000 women volunteers. All of the 34,018 women in this study underwent detailed evaluation of their diets when they entered into this prospective public health study. Among this very large group of women, 629 new cases of breast cancer were diagnosed during the course of this ongoing study. Based upon their self-reported dietary patterns, the women participating in this large epidemiological study were divided into two groups. The first group consisted of women who regularly consumed cruciferous vegetables, fruit, and tofu. The second group of women generally favored meat and starchy foods (such as dim sum), and consumed far fewer portions of vegetables, fruit, and tofu when compared to the first group. The results of this study indicated that increasing levels of vegetable, fruit and tofu intake were associated with a significant decrease in breast cancer risk in postmenopausal women. Among the women reporting the highest levels of intake of these foods, there was, on average, a 30 percent reduction in the risk of breast cancer when compared to the women who rarely ate these healthy foods. Moreover, among the postmenopausal women who frequently consumed vegetables, fruit, and tofu, and who were observed for 5 or more years in this study, the apparent reduction in the risk of breast cancer grew even stronger, and these women were found to be 43 percent less likely to develop breast cancer when compared to women who rarely consumed vegetables, fruit, and tofu in their diets. Therefore, in this large diet survey-based, prospective public health study, a diet rich in vegetables (and cruciferous vegetables, such as broccoli and cauliflower, in particular), fruit, and tofu was strongly associated with a significant reduction in breast cancer risk in postmenopausal Chinese women living in Singapore. Although there remains some concern that soy isoflavones may, under some conditions, actually stimulate the growth of either new or previous breast cancers (or cancers of the ovary or uterus), this public health study’s favorable findings are additive to a growing body of research data suggesting that both cruciferous vegetables and soy-derived isoflavones may be associated with a substantial decrease in the risk of breast cancer in women.
To learn more about the potential role of cruciferous vegetables and soy isoflavones as part of a cancer prevention lifestyle, look for the publication of my new landmark evidence-based book, “A Cancer Prevention Guide for the Human Race,” in the summer of this year. Disclaimer: As always, my advice to readers is to seek the advice of your physician before making any significant changes in medications, diet, or level of physical activity Dr. Wascher is an oncologic surgeon, a professor of surgery, a cancer researcher, an oncology consultant, and a widely published author For a different perspective on Dr. Wascher, please click on the following YouTube link: http://www.youtube.com/watch?v=7-Tdv7XW0qg I and the staff of Weekly Health Update would like to take this opportunity to thank the nearly 120,000 new and returning readers who visited our premier global health information website last month. As always, we enjoy receiving your stimulating feedback and questions, and I will continue to try and personally answer as many of your inquiries as I possibly can. In view of the extreme devastation and human misery brought about in Haiti and Chile by the recent earthquakes, Weekly Health Update asks our tens of thousands of caring readers to give generously to established charities that are currently working in those countries to assist the injured, the ill, and the homeless. There are many such legitimate charities, including the following two: http://www.imcworldwide.org/haiti |
|
|
CT Scans & Cancer Risk
December 20, 2009 by admin
Filed under CT Scans, Cancer, Cancer Prevention
Welcome to Weekly Health Update“A critical weekly review of important new research findings for health-conscious readers”
HAPPY HOLIDAYS FROM WEEKLY HEALTH UPDATE!
CT SCANS & CANCER RISK
CT (computed tomography) scanners have revolutionized the practice of medicine since they were first introduced into routine clinical practice in 1974. CT scanners utilize a rotating x-ray device to create hundreds of individual images that can then be reconstructed into a complex three dimensional view of the body by computers. Current generation CT scanners are able to image the entire human body within seconds, and these high definition images provide physicians with an incredibly detailed view of the organs and tissues deep within us.
CT scanners have become an indispensible diagnostic tool within virtually every medical and surgical specialty, and an estimated 75 million CT scans are now performed annually in the United States, alone. As the popularity of these complex and powerful diagnostic imaging machines has continued to grow, so has their use for clinically dubious reasons. For example, routine scans of the heart, and its coronary arteries, have, increasingly, been used for “screening purposes” in patients without any clinical evidence of heart disease. Likewise, there has been an explosion in the number of private radiology imaging centers offering fee-based “body scans” for clinically healthy people who are interested in having their internal organs examined for any early signs of diseases that can be detected by CT scans. Another area of concern regarding the use of CT scanners is that physicians have become so dependent on these machines, and the exquisite images of the human body that they provide, that many (if not most) doctors have a very low threshold to order CT scans as a routine part of their diagnostic work-up of patients. (For example, in my own specialty of Surgery, the diagnosis of appendicitis is now routinely made with a CT scanner, rather than by the traditional method of the surgeon’s clinical evaluation of the patient.)
While CT scanners have become essential diagnostic tools, they also expose patients to much higher doses of radiation than most conventional x-ray examinations. It has long been known that exposure to radiation increases the risk of developing cancer, and that the risk of developing cancer is proportional to the dose of radiation received by patients. (Based upon recent estimates, it has been estimated that at least 2 percent of all cancer cases may be caused by prior exposure to medical x-rays.) Moreover, there is no known “safe” dose of radiation in terms of radiation-induced cancer risk. As if this was not already bad enough, there has been a growing concern regarding the actual dose of radiation that is being delivered to patients from CT scanners across the country, as there is a great deal of variability in the radiation dose settings being used among different CT scan imaging facilities. (This alarming point was recently brought to the public’s attention when it was revealed that Cedars Sinai Medical Center, a prestigious private hospital in the Beverly Hills area, was being investigated after multiple patients who had undergone CT scans of their brain there began to notice that their hair was falling out. Authorities subsequently determined that these patients had received grossly excessive radiation doses during their scans.)
Two very important public health studies have just been published in the Archives of Internal Medicine, and the findings of these two related studies have significantly raised the level of concern regarding the current use of CT scanners among public health experts.
The first of these two studies quantified the amount of radiation dose delivered to 1,119 patients for 11 common types of CT scan examinations that were performed at 4 different hospitals in the San Francisco area. In addition to calculating the radiation doses received by these patients, the authors also estimated the probable lifetime cancer risk associated with these CT scans. As the Cedars Sinai case has already shown, there appears to be considerable variability in the amount of radiation used at different institutions to conduct the same exact type of CT scan. However, the sheer magnitude of this variability in radiation doses, as measured by these researchers, is both mind-boggling and disturbing. Not only was there an enormous difference in radiation doses associated with performing the same exact type of CT scan between the 4 different institutions that were studied, but significant radiation exposure differences were also present within each individual institution when performing the same type of CT scan examination on different patients. When the researchers had finished their calculations, they noted an almost unbelievable 13-fold difference, on average, in radiation exposure for the same type of CT scan between the highest and lowest observed radiation doses for each individual type of CT examination.
Based largely upon cancer incidence data collected after the Hiroshima and Nagasaki atomic bombings, this clinical study’s researchers calculated that an estimated 1 in 270 women who underwent a CT scans of their coronary arteries at age 40 will eventually develop cancer as a direct result of these CT scans (versus 1 in 600 men), while 1 in 8,100 women who underwent CT scans of the brain at age 40 will develop cancer from these scans (versus 1 in 11,080 men). For men and women who underwent CT scans at age 20 (instead of age 40), the projected lifetime risk of CT scan-associated cancer was nearly double the projected risk of the 40 year-old patients.
The findings of this study indicate that the variability in radiation exposure between hospitals for the same type of CT scan examination is much greater than was previously believed. Perhaps even more surprising was the finding that identical CT scan examinations performed within a single hospital also subjected patients to significantly different amounts of radiation exposure. Finally, the calculated range of radiation exposure for CT scans revealed that, in general, patients are receiving far higher doses of radiation from routine CT scans than has generally been appreciated. (For example, a single CT coronary artery angiogram delivers the same amount of radiation as 310 chest x-rays!)
The second research study used public health data to estimate the average number of radiation-induced cancers caused by CT scans in the United States. Based upon current CT scan use, these researchers predicted that approximately 29,000 future cases of cancer could be expected to arise from CT scans performed in 2007 in the United States, resulting in approximately 15,000 deaths due to cancers caused directly by CT scans!
These two studies are eye-openers that should cause all of us, physicians and patients alike, to reconsider the benefits versus the risks of each and every CT scan that is considered before such scans are performed. Although most CT scans are performed because they offer vitally important clinical information on patients that could only otherwise be obtained by surgical exploration, too many CT scans are still being ordered and performed for far less compelling reasons (one of them being, unquestionably, the tendency of many physicians to order multiple unnecessary tests on patients as part of their practice of “defensive medicine,” in the absence of tort reform throughout most areas of the United States…). Moreover, the striking variation in CT-associated radiation doses, and the unexpectedly high level of these radiation doses in general, points to the need to improve standardization and compliance at every one of the thousands of institutions in the United States that operates a CT scanner. As a dedicated cancer specialist, I am already well aware of the potential for radiation-induced cancers, and I have, for many years, tried to be very selective in ordering CT scans on my patients. In cases where I can gather the necessary clinical information without resorting to radiographic imaging, then I try to avoid obtaining any form of x-ray examination (including CT scans). In other cases, where I must obtain some sort of imaging examination, then I will often initially use ultrasound or MRI studies in place of CT scans, when appropriate. Even so, the dramatic findings of these two studies suggest to me that all physicians need to further decrease their routine use of CT scans whenever possible.
Disclaimer: As always, my advice to readers is to seek the advice of your physician before making any significant changes in medications, diet, or level of physical activity Dr. Wascher is an oncologic surgeon, a professor of surgery, a cancer researcher, an oncology consultant, and a widely published author
|
|
|
Soy Isoflavones Reduce Breast Cancer Recurrence Risk
December 13, 2009 by admin
Filed under Breast Cancer, Cancer, Cancer Prevention, Isoflavones, Nutrition, Soy, diet, health
Welcome to Weekly Health Update“A critical weekly review of important new research findings for health-conscious readers”
SOY ISOFLAVONES REDUCE BREAST CANCER
RECURRENCE RISK
Regular readers of this column are already aware of the controversy surrounding soy isoflavone intake and breast cancer risk. As happens frequently in clinical research (unfortunately), contradictory research findings have made it difficult to understand the true relationship between dietary soy intake and breast cancer risk (if one exists). There is, for example, both laboratory and clinical data suggesting that a diet rich in soybean-derived products may be associated with a lower risk of developing breast cancer. At the same time, because genistein and other dietary isoflavones are known to weakly mimic the effects of estrogen, there has been some concern that a diet rich in isoflavone “phytoestrogens” may increase both the risk of developing a new breast cancer and the risk of developing a recurrence of a previous breast cancer. (In fact, there is data from laboratory research studies showing that genistein can indeed fuel the growth of human breast cancer cells growing in culture dishes, when exposed to high concentrations of this soy-derived isoflavone.)
A growing body of public health research, primarily from Asian countries where tofu and other soy-based foods are frequently consumed, appears to link increased soy consumption with a decreased lifetime breast cancer risk, particularly when soy-based foods are consumed during adolescence, during the time when development of the female breast is most active (Soy & Breast Cancer Risk). (Interestingly, there is also recent research suggesting that soy products might also reduce the risk of prostate cancer, which is another hormonally driven cancer: Genistein & Prostate Cancer Cells, Dietary Soy & Prostate Cancer Risk.)
Although epidemiological research is, increasingly, suggesting that a diet rich in soybean-derived foods might lower a woman’s lifetime risk of developing breast cancer, many breast cancer experts have remained apprehensive regarding dietary isoflavone intake in women with a prior history of breast cancer, in view of the estrogen-like effects of these “phytoestrogens.” As I have already noted, there is considerable research data available to suggest that soy-derived isoflavones can, at least under certain laboratory conditions, stimulate estrogen-sensitive breast cancer cells to grow and divide. These research findings have left many oncologists feeling uncomfortable in recommending soy-based foods to their breast cancer patients. Now, a newly publish public health study in the Journal of the American Medical Association suggests that soy-based foods may actually reduce the risk of breast cancer recurrence, and death due to any cause, in women who have previously been diagnosed with this very common form of cancer.
In this study, which was performed in Shanghai, China, 5,042 female breast cancer survivors (ages 20 to 75 years) were followed for an average of almost 4 years. All of these patient volunteers underwent detailed surveys regarding their lifestyle habits, including their diets. These patients, who were originally diagnosed with breast cancer between 2002 and 2006, were surveyed at 6, 18, 36 and 60 months following their original diagnosis with breast cancer.
The results of this study indicate that the breast cancer survivors who consumed the greatest amount of soy-based foods in their daily diets were 32 percent less likely to experience a recurrence of their breast cancer when compared to the women who consumed the least amount of soy-based isoflavones. Moreover, the women who consumed the greatest amount of soy were also 29 percent less likely to die, from any cause, when compared to the women who consumed the least amount of soy-derived foods.
A particularly interesting and unexpected finding of this study was that both women with estrogen sensitive breast cancers and women with tumors that were not sensitive to estrogen appeared to experience a significantly decreased risk of breast cancer recurrence if they frequently consumed soy products. Another important finding of this study was that women who were taking the estrogen-blocking cancer treatment drug tamoxifen also appeared to enjoy a reduced risk of breast cancer recurrence with higher levels of dietary soy intake. Additionally, the researchers noted that high levels of soy intake appeared to be about as effective in reducing the risk of breast cancer recurrence as the breast cancer prevention drug tamoxifen, alone.
The results of this very important study mirror the findings of the only other prospective clinical study that has looked at the impact of soy-based foods on breast cancer recurrence (the “Life After Cancer Epidemiology,” or “LACE,” study). The LACE study, which was performed in the United States, followed nearly 2,000 breast cancer survivors for, on average, more than 6 years. In the LACE study, women who were taking tamoxifen, and who also consumed the highest amount of soy-based dietary isoflavones, were 50 percent less likely to develop a recurrence of their breast cancer when compared to women who reported the lowest consumption of soy-derived foods.
As I have pointed out previously, epidemiological research studies based upon dietary surveys are susceptible to several types of bias which, in turn, can cause researchers to draw the wrong conclusions. In this case, however, there are now two large prospective cohort studies that have reached essentially the same conclusions (albeit with a rather limited duration of patient follow-up). Both studies strongly suggest that high levels of soy-based isoflavones in the diet may be able to significantly reduce the risk of breast cancer recurrence. Based upon the findings of this large Chinese study, the apparent cancer risk reduction effect associated with high levels of soy intake also appears to benefit premenopausal and postmenopausal women, as well as women who are taking the estrogen-blocking drug tamoxifen, women with estrogen-sensitive tumors, and women with (counter-intuitively) estrogen-resistant tumors.
In view of the limited duration of patient follow-up in both of these clinical breast cancer studies, as well as the limitations of survey-based epidemiological research in general, I would like to see updated data from both of these studies after at least 10 years of patient observation before I would be willing to tell my breast cancer patients that they should significantly increase their dietary soy intake. On the other hand, the rather compelling data presented by both of these clinical research studies will also make me less anxious when any of my breast cancer patients decide, of their own accord, to increase their intake of soy-derived isoflavones.
Note: Weekly Health Update is currently undergoing an extensive upgrade to better serve its tens of thousands of health-conscious readers around the world. Beginning in January 2010, newly archived columns will be available by selecting the “Archives” tab on the right side of your screen (all archived columns prior to January 2010 will continue to be available by selecting the “Archives 2007-2009” tab at the top of the screen.)
Disclaimer: As always, my advice to readers is to seek the advice of your physician before making any significant changes in medications, diet, or level of physical activity Dr. Wascher is an oncologic surgeon, a professor of surgery, a cancer researcher, an oncology consultant, and a widely published author
|
Exercise & Prostate Cancer Risk
November 29, 2009 by admin
Filed under Cancer, diet, health, prostate cancer
Welcome to Weekly Health Update
“A critical weekly review of important new research findings for health-conscious readers”
EXERCISE & PROSTATE CANCER RISK There is an increasing body of research evidence to suggest that many cases of cancer can be prevented through lifestyle and diet modifications. Indeed, even conservative estimates suggest that more than 60 percent of new cancer cases could be prevented simply by abstaining from unhealthy lifestyle and dietary habits. (More enthusiastic cancer prevention experts have suggested that 80 percent of cancer cases, or more, might be preventable with rigorous lifestyle and diet changes.) Given that, in the best case, modern cancer treatment results in the long-term survival of only about 60 percent of all cancer patients, and that the survival rate for many of the most lethal cancers still remains far more dismal, an ounce of cancer prevention is certainly worth much more than a pound of cancer cure. (This simple yet profound realization is the central theme of my new book, “A Cancer Prevention Guide for the Human Race,” which will be published in the spring of 2010.)
Disclaimer: As always, my advice to readers is to seek the advice of your physician before making any significant changes in medications, diet, or level of physical activity Dr. Wascher is an oncologic surgeon, a professor of surgery, a cancer researcher, an oncology consultant, and a widely published author
|
